FEIBA NF (anti-inhibitor coagulant complex)
ANTIHEMOPHILIC INHIBITOR PRODUCTS · BLEEDING EPISODE IN HEMOPHILIA A ·+2
BAXALTA US INC.
Drug class
Antihemophilic Inhibitor Products
"Antihemophilic Inhibitor Products" is an administrative and compendial drug classification rather than a standard pharmacological class, primarily encompassing bypassing agents such as anti-inhibitor coagulant complex (activated prothrombin complex concentrate). Read more about Antihemophilic Inhibitor Products
3 drugs in this class 2 manufacturers
Drugs in Antihemophilic Inhibitor Products
FEIBA (anti-inhibitor coagulant complex)
ANTIHEMOPHILIC INHIBITOR PRODUCTS · BLEEDING EPISODE IN HEMOPHILIA A ·+2
Takeda Pharmaceuticals America
FEIBA (anti-inhibitor coagulant complex)
ANTIHEMOPHILIC INHIBITOR PRODUCTS · BLEEDING EPISODE IN HEMOPHILIA A ·+2
BAXALTA US INC.
Filter & compare in the drug finder →
Opens the drug finder with Antihemophilic Inhibitor Products preselected. Add indication or manufacturer filters there.
"Antihemophilic Inhibitor Products" is an administrative and compendial drug classification rather than a standard pharmacological class, primarily encompassing bypassing agents such as anti-inhibitor coagulant complex (activated prothrombin complex concentrate).
These biological therapies work by supplying activated clotting factors—primarily factors II, VII, IX, and X—to bypass the need for factor VIII or factor IX in generating thrombin and restoring the coagulation cascade.
Clinically, these agents are indicated for the control, prevention, and perioperative management of bleeding episodes in individuals with hemophilia A or hemophilia B who have developed neutralizing alloantibodies (inhibitors) against standard replacement factors, as well as in patients with acquired hemophilia.
-
fda.gov
"Antihemophilic Inhibitor Products" is an administrative and compendial drug classification rather than a standard pharmacological class, primarily encompassing bypassing agents such as anti-inhibitor coagulant complex (activated prothrombin complex concentrate)
-
connectrx.com
"Antihemophilic Inhibitor Products" is an administrative and compendial drug classification rather than a standard pharmacological class, primarily encompassing bypassing agents such as anti-inhibitor coagulant complex (activated prothrombin complex concentrate) These biological therapies work by supplying activated clotting factors—primarily factors II, VII, IX, and X—to bypass the need for factor VIII or factor IX in generating thrombin and restoring the coagulation cascade
-
fda.gov
Clinically, these agents are indicated for the control, prevention, and perioperative management of bleeding episodes in individuals with hemophilia A or hemophilia B who have developed neutralizing alloantibodies (inhibitors) against standard replacement factors, as well as in patients with acquired hemophilia
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.